Libo-B (09887.HK) Core Product Velsin Granted Orphan Drug Designation in Japan

Zhito Finance APP News: LBL-B (09887.HK) announced that the company's core product Lixin (opamtisumab, a PD-L1/4-1BB bispecific antibody) has been granted orphan drug designation by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third orphan drug designation obtained by Lixin following those from the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of Lixin's global regulatory recognition footprint into a major Asian market.